XWAR
MRC
Market cap129mUSD
Jul 09, Last price
53.50PLN
1D
3.48%
1Q
1.52%
Jan 2017
181.73%
IPO
265.19%
Name
Mercator Medical SA
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Mercator Medical S.A., operating with its subsidiaries, is a key player in the manufacturing and international supply of essential disposable medical provisions. Their primary offerings encompass a broad spectrum of medical gloves, including surgical, protective, sterile examination, and household types, alongside various wound dressings and products made from non-woven fabrics. The company's extensive inventory also features a comprehensive range of single-use apparel like caps, face masks, surgical gowns, shoe covers, staff shirts, sleeve protectors, and patient gowns. Furthermore, Mercator Medical provides specialized surgical items such as drape sheets, unique sterile drapes with non-adhesive openings, complete surgical kits, and a variety of accessories like apparatus and table covers, limb protectors, camera covers, adhesive instrument pockets, and self-adhesive nonwoven tapes. These products are sold under a strong collection of brands, including nitrylex, opero, MERCATOR, Ansell, dermagel, santex, comfort, vinylex, iNtouch, ambulance, and ideal. Their customer base is diverse, spanning medical clients such as healthcare facilities, industrial settings requiring medical supplies, retail chains, and pharmaceutical wholesalers, as well as a wide array of other sectors including beauty, hospitality (hotels, restaurants, catering), cleaning services, agri-food, automotive, home and garden, education, and general retail. Established in 1989, Mercator Medical S.A. is based in Kraków, Poland, and functions as a subsidiary of Anabaza RAIF V.C.I.C. Ltd.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||